Month: July 2025

Release – Century Lithium Commends First Phosphate in Making LFP Battery Cells Using Century Lithium Material

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CYDVF

July 8, 2025 – Vancouver, Canada – Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) (“Century Lithium” or “the Company”) congratulates First Phosphate Corp. (“First Phosphate”) (CSE: PHOS) (OTCQB: FRSPF) (FSE: KD0) on successfully producing commercial-grade lithium iron phosphate (“LFP”) 18650 format battery cells, as reported in First Phosphate’s news release on July 7, 2025. The LFP cathode and anode materials for the First Phosphate 18650 LFP battery cells were produced using North American critical minerals, which included lithium carbonate derived from Century’s Angel Island and produced at Century’s Demonstration Plant in Nevada, USA, as well as high-purity phosphoric acid and iron powder from First Phosphate’s Bégin-Lamarche property in Quebec, Canada.

 “Century Lithium is very pleased that First Phosphate found our lithium carbonate suitable for use in producing LFP battery cells,” said Bill Willoughby, Century Lithium President and CEO. “Century Lithium continues to advance Angel Island through permitting, engineering, and innovation at the Company’s Demonstration Plant in Nevada. We see a bright future for lithium-based chemistries. We believe LFP batteries, in particular, will have an important place in the future of mobile and stationary energy storage systems. We look forward to continuing to support First Phosphate as we work together to strengthen the North American supply chain.”

The LFP 18650 battery cells were assembled for First Phosphate by Ultion Technologies Inc. at their pilot facility in Las Vegas, Nevada.

The production process can be viewed at: firstphosphate.com/NorthAmericanBatteryCells

ABOUT FIRST PHOSPHATE CORP.

First Phosphate Corp. is a mineral development company focused on producing high purity phosphoric acid and iron powder for the Lithium Iron Phosphate (“LFP”) battery industry from its properties in Quebec, Canada. First Phosphate’s industry partners include American Battery Factory Inc., developer of a planned LFP battery gigafactory in Tucson, Arizona, and Ultion Technologies Inc. a battery technology company specializing in LFP battery materials and cells. First Phosphate obtained interest in financing its production of purified phosphoric acid from the Export-Import Bank of the United States (“EXIM”) (firstphosphate.com/exim) and is working towards funding from the United States Department of Defense (“DoD”) Defense Industrial Base Consortium (“DIBC”) (firstphosphate.com/DOD-white-paper).

To learn more about First Phosphate Corp., please visit firstphosphate.com

ABOUT CENTURY LITHIUM CORP.

Century Lithium Corp. is an advanced stage lithium company, focused on developing its wholly owned Angel Island project in Esmeralda County, Nevada, which hosts one of the largest sedimentary lithium deposits in the United States. The Company has utilized its patent-pending process for chloride leaching combined with direct lithium extraction to make battery-grade lithium carbonate product samples from Angel Island’s lithium-bearing claystone on-site at its Demonstration Plant in Amargosa Valley, Nevada.

Angel Island is one of the few advanced lithium projects in development in the United States to provide an end-to-end process to produce battery-grade lithium carbonate for the growing electric vehicle and battery storage market. Angel Island is currently in the permitting stage for a three-phase feasibility-level production plan expected to yield an estimated life-of-mine average of 34,000 tonnes per year of carbonate over a 40-year mine-life.

To learn more, please visit centurylithium.com

ON BEHALF OF CENTURY LITHIUM CORP.

WILLIAM WILLOUGHBY, PhD., PE
President & Chief Executive Officer

For further information, please contact:
Spiros Cacos | Vice President, Investor Relations
Direct: +1 604 764 1851
Toll Free: 1 800 567 8181
scacos@centurylithium.com
centurylithium.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

Cautionary Note Regarding Forward-Looking Statements

This release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” and similar expressions suggesting future outcomes or statements regarding an outlook.

Forward-looking statements relate to any matters that are not historical facts and statements of our beliefs, intentions and expectations about developments, results and events which will or may occur in the future, without limitation, statements with respect to the potential development and value of the Project and benefits associated therewith, statements with respect to the expected project economics for the Project, such as estimates of life of mine, lithium prices, production and recoveries, capital and operating costs, IRR, NPV and cash flows, any projections outlined in the Feasibility Study in respect of the Project, the permitting status of the Project and the Company’s future development plans.

These and other forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. These risks include those described under the heading “Risk Factors” in the Company’s most recent annual information form and its other public filings, copies of which can be under the Company’s profile at www.sedarplus.com. The Company expressly disclaims any obligation to update-forward-looking information except as required by applicable law. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place reliance on forward-looking statements or information. Furthermore, Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.

Release – Conduent Transportation Implements EMV Contactless Payment System for Navigazione Laghi’s Boat Fleet in Italy

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CNDT

July 08, 2025

Transportation

One of the first contactless payment systems introduced for boat transportation in Italy

MILAN & FLORHAM PARK, N.J. — Conduent Transportation, a global provider of smart mobility technology solutions and business unit of Conduent Incorporated (Nasdaq: CNDT), has implemented a new EMV (Europay, Mastercard, and Visa) contactless payment system for Gestione Governativa Navigazione Laghi, the government agency of the Ministry of Infrastructure and Transport that operates a fleet of boats on Lakes Maggiore, Garda, and Como in northern Italy. This marks one of the first EMV contactless payment systems deployed for boat transportation in Italy.

Enhancing Passenger Convenience Through Digitalization

The new contactless payment system simplifies transactions for passengers by enabling tap-in and tap-out payments using the on-board validators with contactless debit and credit cards, as well as NFC-enabled digital wallets. This advancement modernizes the fare structure and facilitates the digitalization of payments, making travel more seamless and efficient.

Complementing the electronic ticketing system previously implemented by Conduent at ticket offices across the three lakes, this new solution enhances on-board accessibility, facilitating a smooth travel experience for the 12 million passengers Navigazione Laghi serves annually.

“Operating an efficient, passenger-friendly boat fleet is vital to the transportation network on Lakes Maggiore, Garda, and Como, which are some of Italy’s most visited destinations,” said Pietro Marrapodi, Government Manager at Navigazione Laghi. “As part of the public tender won by Conduent, we first introduced electronic ticketing, and now we’ve further enhanced the system with EMV contactless payment. This upgrade gives passengers more flexible ticketing options, ensuring a seamless travel experience.”

Industry Leaders in EMV Payment Systems for Transportation

“Navigazione Laghi’s adoption of contactless EMV payment systems reflects a global shift toward digitalized ticketing,” said Jean-Charles Zaia, President, Transit Solutions at Conduent. “Across the world, transportation authorities are modernizing their systems, encouraging wider adoption of EMV payment methods. Contactless EMV solutions make travel easier for passengers while enabling dynamic and flexible fare management – key benefits of public transport digitalization.”

Conduent fare collection systems are in use on more than 400 public transit networks of all sizes around the world. In July 2024, Conduent announced that it had launched a contactless payment system on the Venice transportation network managed by Azienda Veneziana della Mobilità (AVM).

Conduent Transportation is a leading provider of streamlined, high-volume mobility services and solutions, spanning tolling and advanced transit systems, which enhance the services provided by transportation agencies to benefit the citizens who use them. For over 50 years, the company has helped clients advance transportation solutions in more than 20 countries.

About Conduent

Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 56,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $85 billion in government payments annually, enabling 2.3 billion customer service interactions annually, empowering millions of employees through HR services every year and processing nearly 13 million tolling transactions every day. Learn more at www.conduent.com.

Note: To receive RSS news feeds, visit www.news.conduent.com. For open commentary, industry perspectives and views, visit http://twitter.com/Conduent, http://www.linkedin.com/company/conduent or http://www.facebook.com/Conduent.

Trademarks

Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

Media Contacts

Robert Corbishley

Conduent

Robert.Corbishley@conduent.com

+44 (0) 7703 516569

David Chen

Conduent

ir@conduent.com

Neil Franz

Conduent

neil.franz@conduent.com

+1-240-687-0127

Release – Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Posted on by aweinsoff@channelchek.com

Research News and Market Data on UNCY

July 08, 2025 8:30am EDT Download as PDF

–Nasdaq compliance follows reverse stock split previously announced on June 17, 2025

LOS ALTOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced it has regained compliance with the Nasdaq Stock Market (“Nasdaq”) continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. This update was disclosed in the Company’s Current Report on Form 8-K filed on July 8, 2025.

On July 7, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of July 3, 2025 the Company’s common stock has maintained an average closing share price of at least $1.00 immediately following the Company’s 1:10 reverse stock split that became effective on June 20, 2025 The Company’s shares are no longer considered to be below the minimum bid price requirement of Rule 5550(a)(2), and as a result the Company has regained compliance with the Nasdaq continued listing standard. Nasdaq now considers this matter closed.

About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Media Contact:
Rachel Visi
Real Chemistry
redery@realchemistry.com

Primary Logo

Source: Unicycive Therapeutics, Inc.

Released July 8, 2025

Release – MariMed Announces Second Quarter 2025 Earnings Date

Posted on by aweinsoff@channelchek.com

Research News and Market Data on MRMD

July 08, 2025 7:30am EDT Download as PDF

NORWOOD, Mass., July 08, 2025 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed” or “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today it will report second quarter 2025 financial results on August 6, 2025 after the markets close. Management will host a conference call on August 7, 2025 at 8:00 a.m. EDT to discuss financial results.

A webcast will be available and can be accessed via MariMed’s Investor Relations website at MariMed Q2 2025 Earnings Webcast. A playback of the call will also be made available on MariMed’s Investor Relations website.

About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies™, Bubby’s Baked™, InHouse™, Nature’s Heritage™, and Vibations™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Company Contact:
Howard Schacter
Chief Communications Officer 
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

Primary Logo

Source: MariMed Inc.

Released July 8, 2025

E.W. Scripps (SSP) – Strengthening Its Station Portfolio

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, July 08, 2025

The E.W. Scripps Company (NASDAQ: SSP) is a diversified media company focused on creating a better-informed world. As one of the nation’s largest local TV broadcasters, Scripps serves communities with quality, objective local journalism and operates a portfolio of 61 stations in 41 markets. The Scripps Networks reach nearly every American through the national news outlets Court TV and Newsy and popular entertainment brands ION, Bounce, Defy TV, Grit, ION Mystery, Laff and TrueReal. Scripps is the nation’s largest holder of broadcast spectrum. Scripps runs an award-winning investigative reporting newsroom in Washington, D.C., and is the longtime steward of the Scripps National Spelling Bee. Founded in 1878, Scripps has held for decades to the motto, “Give light and the people will find their own way.”

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Compelling station swap. Scripps will be selling its stations in Lansing MI and Lafayette LA to Gray Television (GTN: Not Rated) and buying stations in Colorado Springs, CO and Grand Junction, CO and a station in Twin Falls ID. We view the move favorably, given that Scripps will create station duopolies and strengthen its presence in the West. We believe that the move will create significant efficiencies for both companies, eliminating back office, duplicative, and overhead costs. This will be an even swap with no cash compensation to either party. 

FCC fast track? The FCC has signaled its willingness to fast track the regulatory process, likely to provide a “waiver” to create duopolies rather than to seek a longer review/rulemaking process. As such, we believe that the transaction could be completed by year end. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Xcel Brands (XELB) – Seeking Fuel For Growth

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, July 08, 2025

Xcel Brands, Inc. 1333 Broadway 10th Floor New York, NY 10018 United States https:/Sector(s): Consumer Cyclical Industry: Apparel Manufacturing Full Time Employees: 84 Key Executives Name Title Pay Exercised Year Born Mr. Robert W. D’Loren Chairman, Pres & CEO 1.27M N/A 1958 Mr. James F. Haran CFO, Principal Financial & Accou

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Files S1. The company plans to sell 1.381 million shares on a “best efforts” basis and pre-funded warrants. Pre-funded warrants are exercisable at any time after the date of issuance and may be exercised at any time. Notably, management has indicated its interest in participating in the offering for up to 10% of the shares. Following the prospective sale, total shares outstanding would increase to 3.819 million shares. 

Use of proceeds. Based on the current stock price and assuming all shares are sold, management expects to generate roughly $1.9 million in net proceeds from the offering. The company plans to use the proceeds for working capital and general corporate purposes and toward a $50,000 principal loan payment to a company controlled by Robert D’Loren, the company’s Chairman and CEO. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Alliance Resource Partners (ARLP) – Outlook Remains Favorable, Increasing 2025 Estimates

Posted on by slightbourne@noblecapitalmarkets.com


Tuesday, July 08, 2025

ARLP is a diversified natural resource company that generates operating and royalty income from coal produced by its mining complexes and royalty income from mineral interests it owns in strategic oil & gas producing regions in the United States, primarily the Permian, Anadarko and Williston basins. ARLP currently produces coal from seven mining complexes its subsidiaries operate in Illinois, Indiana, Kentucky, Maryland and West Virginia. ARLP also operates a coal loading terminal on the Ohio River at Mount Vernon, Indiana. ARLP markets its coal production to major domestic and international utilities and industrial users and is currently the second largest coal producer in the eastern United States. In addition, ARLP is positioning itself as an energy provider for the future by leveraging its core technology and operating competencies to make strategic investments in the fast growing energy and infrastructure transition.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Updating estimates. We are increasing our 2025 adjusted EBITDA and EPU estimates to $676.5 million and $2.55, respectively, from $672.6 million and $2.52. We increased our crude oil and natural gas price estimates based on CME futures settlements, which had a positive impact on oil and gas royalty revenue. Our 2026 adjusted EBITDA and EPS estimates are unchanged at $678.3 million and $2.60, respectively. While management expects the average coal sales price per ton to trend lower in 2026 due to higher-priced contracts rolling off, we think 2025 longwall moves and actions to improve productivity and cost effectiveness could help offset the impact of lower prices.

Recent legislation expected to benefit the fossil fuel industry. Following several executive orders earlier in the year intended to support the coal industry and delay coal power plant retirements, the Big Beautiful Bill (BBB) was signed into law on July 4 and is expected to benefit the fossil fuel industry. Among other things, the BBB phases out many of the clean energy tax credits established under the Inflation Reduction Act and creates a supportive environment for oil, gas, and coal production.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Royal Gold to Acquire Sandstorm Gold and Horizon Copper, Creating a Global Streaming and Royalty Powerhouse

Posted on by slightbourne@noblecapitalmarkets.com

In a landmark move set to reshape the metals royalty landscape, Royal Gold Inc. announced it will acquire Sandstorm Gold Royalties and Horizon Copper in two separate transactions valued at over $3.7 billion. The acquisitions will create a large-scale, highly diversified precious metals streaming and royalty company poised to lead the industry in both scale and growth potential.

Under the agreement with Sandstorm Gold Ltd., Royal Gold will acquire all outstanding Sandstorm shares in an all-stock transaction worth approximately $3.5 billion. Sandstorm shareholders will receive 0.0625 shares of Royal Gold for each Sandstorm share, representing a 21% premium to Sandstorm’s 20-day volume-weighted average price. Once completed, Sandstorm shareholders will own roughly 23% of the combined company.

Concurrently, Royal Gold will acquire Horizon Copper Corp. in an all-cash transaction valued at approximately $196 million. Horizon shareholders will receive C$2.00 per share—a substantial 85% premium to Horizon’s 20-day VWAP. These two deals are expected to close in the coming months, pending regulatory and shareholder approvals.

Strategic Synergies and Portfolio Expansion

The combined entity will emerge with a portfolio of 393 royalty and streaming assets, including 80 cash-flowing properties. Importantly, no single asset will represent more than 13% of the company’s net asset value, demonstrating a high level of diversification. Approximately 87% of the combined revenue will be derived from precious metals, with 75% from gold.

Notable producing assets include Mount Milligan in Canada, Pueblo Viejo in the Dominican Republic, Cortez in Nevada, and Andacollo in Chile. These high-quality, long-life operations provide a stable foundation for future cash flows. Development assets like MARA, Hod Maden, and Platreef promise significant organic growth.

Royal Gold expects to benefit from a strong balance sheet with minimal debt and robust free cash flow generation. The newly formed company will have the financial strength and scale to pursue additional growth opportunities, while enhancing its appeal to institutional investors.

Leadership Vision and Outlook

Sandstorm CEO Nolan Watson emphasized the strategic fit, highlighting that the merger delivers immediate value to shareholders while retaining exposure to future upside. He praised Sandstorm’s legacy of innovation and expressed confidence in Royal Gold’s ability to carry the torch forward.

Royal Gold CEO Bill Heissenbuttel echoed the sentiment, noting that the transactions align with the company’s long-standing strategy of disciplined growth in mining-friendly jurisdictions. He described the merger as a transformative step that creates an unmatched global portfolio of high-quality, long-life precious metal assets.

With enhanced scale, improved trading liquidity, and a proven track record of shareholder returns, the newly combined Royal Gold is expected to achieve a premium valuation and expanded market reach. Positioned as a top-tier vehicle for gold exposure in the U.S. marketplace, it is set to become a cornerstone in many institutional and retail investment portfolios.

Investors and analysts alike will be watching closely as this new chapter unfolds, marking a pivotal moment in the evolution of the royalty and streaming sector.

Middle Markets Brace for Impact as Trump’s Tariff Expansion Rattles Markets

Posted on by slightbourne@noblecapitalmarkets.com

Middle market companies across manufacturing, retail, and technology sectors are scrambling to assess potential impacts after President Trump’s Monday announcement of 25% tariffs on Japanese and South Korean imports, set to take effect August 1st. The move sent shockwaves through equity markets, with major indices posting their worst single-day performance in weeks.

The Dow Jones Industrial Average plummeted over 400 points, closing down 1.21%, while the S&P 500 and Nasdaq Composite shed 0.98% and 1.03% respectively. For middle market investors, the selloff signals deeper concerns about how expanding trade tensions could reshape global supply chains and corporate profitability.

Middle market manufacturers with exposure to Japanese and South Korean suppliers face immediate headwinds. Companies in automotive parts, electronics components, and industrial machinery sectors are particularly vulnerable, as these industries rely heavily on specialized inputs from both countries.

Japan remains a critical supplier of precision machinery and automotive components, while South Korea dominates in semiconductors, displays, and advanced materials. The proposed 25% levy could force companies to either absorb significant cost increases or pass them to consumers, potentially crimping demand.

Trump’s escalation extends beyond Asia, with threatened tariffs ranging from 25% to 40% on imports from South Africa, Malaysia, and other nations. The President’s additional 10% levy on countries aligned with BRICS policies adds another layer of complexity for companies with emerging market exposure.

The timing proves particularly challenging as many middle market firms are still recovering from previous trade disruptions. Companies that invested heavily in supply chain diversification following earlier tariff rounds now face the prospect of further reorganization.

Technology-focused middle market companies face dual pressures from both component cost increases and potential retaliation affecting export opportunities. Manufacturing firms with just-in-time inventory systems may need to accelerate stockpiling, tying up working capital.

Retail-oriented middle market companies importing consumer goods from targeted countries could see margin compression if they cannot pass costs to price-sensitive customers. The uncertainty also complicates inventory planning and pricing strategies heading into the crucial back-to-school and holiday seasons.

Despite the volatility, some middle market investors see potential opportunities emerging. Companies with domestic supply chains or those positioned to benefit from supply chain reshoring could gain competitive advantages. Additionally, firms with strong balance sheets may find acquisition opportunities as smaller competitors struggle with increased costs.

Treasury Secretary Scott Bessent’s indication of potential deals in coming days provides some hope for resolution, though markets remain skeptical given the administration’s aggressive timeline. The focus on 18 major trading partners before expanding to over 100 countries suggests a systematic approach, but also highlights the scope of potential disruption.

With earnings season approaching, middle market companies will face intense scrutiny on guidance and cost management strategies. Thursday’s Delta Air Lines report kicks off what many analysts expect to be a challenging quarter for companies with significant international exposure.

The key question for middle market investors remains whether current valuations adequately reflect the potential for prolonged trade tensions. As markets digest the implications of Trump’s latest tariff expansion, portfolio positioning and risk management become increasingly critical for navigating the uncertain landscape ahead.

Trump Escalates Trade War: 25% Tariffs Hit Japan and South Korea

Posted on by slightbourne@noblecapitalmarkets.com

President Trump dramatically escalated his global trade offensive Monday, announcing 25% tariffs on imports from Japan and South Korea while threatening even higher duties on nations aligning with BRICS policies he deems “anti-American.” The move marks a significant expansion of the administration’s protectionist agenda beyond traditional targets like China.

The President posted formal notification letters to both Asian allies on social media, declaring the tariffs would take effect August 1. The announcement caught markets and diplomatic circles off guard, as both Japan and South Korea have been key U.S. allies for decades and major trading partners in critical technology sectors.

Trump’s tariff strategy appears designed to leverage economic pressure for broader geopolitical objectives. In his letter to Japanese Prime Minister, Trump offered a clear carrot-and-stick approach: “There will be no Tariff if Japan, or companies within your Country, decide to build or manufacture product within the United States.”

The administration promises expedited approvals for companies willing to relocate manufacturing operations to American soil, potentially completing the process “in a matter of weeks” rather than the typical months or years required for major industrial projects.

This represents a significant shift from traditional trade diplomacy, using tariff threats as direct incentives for foreign investment and manufacturing relocation. The approach mirrors tactics used successfully with several other trading partners, where the threat of punitive duties has led to increased American manufacturing commitments.

Perhaps most concerning for global trade stability, Trump explicitly warned both countries that any retaliatory tariffs would be met with equivalent increases in U.S. duties. This tit-for-tat escalation mechanism could quickly spiral into a destructive trade war with America’s closest Pacific allies.

The President cited “long-term, and very persistent” trade deficits as justification for restructuring these relationships. Japan previously faced 24% tariffs in April before a temporary pause, while South Korea had been subject to 25% rates, suggesting the administration views these levels as baseline positions rather than maximum penalties.

The tariff announcements represent just the latest moves in Trump’s comprehensive trade realignment strategy. The administration has been systematically addressing trade relationships across multiple continents, with varying degrees of success and diplomatic tension.

Recent developments elsewhere show the mixed results of this approach. China has seen some easing of tensions, with the U.S. relaxing export restrictions on chip design software and ethane following framework agreements toward a broader trade deal. Vietnam reached accommodation with a 20% tariff rate—substantially lower than the 46% originally threatened—though facing 40% duties on transshipped goods.

The European Union has signaled willingness to accept 10% universal tariffs while seeking sector-specific exemptions, indicating established trading blocs are adapting to the new reality rather than engaging in prolonged resistance.

The targeting of Japan and South Korea creates particular challenges given their roles as critical technology suppliers and security partners. Both nations are integral to global semiconductor supply chains, with South Korean companies like Samsung and SK Hynix playing essential roles in memory chip production, while Japanese firms dominate specialized manufacturing equipment and materials.

The timing appears strategic, occurring as the administration faces domestic pressure to demonstrate progress on trade deficit reduction while maintaining leverage in ongoing negotiations with other partners. The threat of duties reaching as high as 70% on some goods creates enormous uncertainty for businesses planning international supply chain strategies.

Canada’s recent decision to scrap its digital services tax affecting U.S. technology companies demonstrates how the tariff threat environment is reshaping international policy decisions. The White House indicated trade talks with Canada have resumed, targeting a mid-July agreement deadline.

This pattern suggests the administration’s approach of combining immediate tariff threats with longer-term negotiation windows may be yielding results in some cases, even as it strains traditional alliance relationships.

As more notification letters are expected today, global markets are bracing for additional announcements that could further reshape international trade relationships and supply chain strategies worldwide.

Release – Bit Digital Shifts Entire Treasury to Ethereum, Becomes One of the Largest ETH Holders Among Public Companies

Posted on by aweinsoff@channelchek.com

Research News and Market Data on BTBT

  • July 7, 2025

Following a $172 million public equity raise and conversion of its balance sheet from Bitcoin to Ethereum, Bit Digital has accumulated over 100K ETH to become one of the largest corporate treasury companies in the world led under Ethereum veteran Sam Tabar

July 7, 2025 /PRNewswire/ — Bit Digital, Inc. (Nasdaq: BTBT) (“Bit Digital” or the “Company”), today announced the completion of its transition to an Ethereum treasury strategy. Following the close of its recent underwritten public offering, the Company raised approximately $172 million in gross proceeds and has deployed the net capital to purchase Ethereum (“ETH”). Additionally, Bit Digital sold approximately 280 BTC and used the proceeds to purchase additional ETH.

Prior to the offering, Bit Digital held 24,434 ETH as of March 31, 2025. Following the additional ETH acquisitions funded by the net proceeds of the public offerings and the sale of its bitcoin position, the Company has accumulated approximately 100,603 ETH.

“We believe Ethereum has the ability to rewrite the entire financial system. Ethereum’s programmable nature, growing adoption, and staking yield model represent the future of digital assets,” said Sam Tabar, Chief Executive Officer of Bit Digital. “Bit Digital is aligning itself with Ethereum’s long-term potential and positioning itself as a focused Ethereum treasury platform in the public markets. We are starting with exposure to over 100K ETH for now but we intend to aggressively add more so we become the preeminent ETH holding company in the world.”

About Bit Digital

Bit Digital is a publicly traded digital asset platform focused on Ethereum-native treasury and staking strategies. The Company began accumulating and staking ETH in 2022 and now operates one of the largest institutional Ethereum staking infrastructures globally. Bit Digital’s platform includes advanced validator operations, institutional-grade custody, active protocol governance, and yield optimization. Through strategic partnerships across the Ethereum ecosystem, Bit Digital aims to deliver exposure to secure, scalable, and compliant access to onchain yield. For additional information, please contact ir@bit-digital.com or follow us on LinkedIn or X.

Investor Notice

Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described under “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024 (Annual Report) and any subsequently filed quarterly reports on Form 10-Q and any Current Reports on Form 8-K.  If any material risk was to occur, our business, financial condition or results of operations would likely suffer. In that event, the value of our securities could decline and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See “Safe Harbor Statement” below.

Safe Harbor Statement 

This press release may contain certain “forward-looking statements” relating to the business of Bit Digital, Inc., and its subsidiary companies. All statements, other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Release – Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

Posted on by aweinsoff@channelchek.com

Research News and Market Data on TNXP

July 07, 2025 7:00am EDT Download as PDF

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox

TNX-801 confers durable protection after a single dose

TNX-801 is well tolerated in immunocompromised animals, without evidence of spreading to blood or tissues even at high doses

CHATHAM, N.J., July 07, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Sina Bavari, PhD, Executive Vice President of Infectious Disease Research and Development at Tonix Pharmaceuticals, will present new data on TNX-801 (recombinant horsepox virus, live vaccine) at the upcoming Vaccine Congress 2025.

TNX-801 is a minimally replicative, attenuated live virus vaccine candidate designed to generate durable humoral and cellular immunity after a single dose. Preclinical results in animals have demonstrated protection against mpox and other orthopoxviruses, supporting further clinical evaluation. TNX-801 also serves as an orthopoxvirus vaccine platform that can deliver multiple protective antigens against diverse viral pathogens.

Dr. Bavari will present the safety, immunogenicity, and efficacy findings to date and describe Tonix’s plans to advance the TNX-801 platform into clinical trials to protect against mpox and other viral diseases.

Presentation details

Location: Vienna, Austria
Presentation Date / Time: July 10th / 11:20am GMT+2
Title: TNX-801, a single-dose live vaccine platform for Mpox and other emerging viral diseases: Safety, Immunogenicity, and Efficacy  
Speaker: Sina Bavari, PhD, Tonix Pharmaceuticals

A copy of the presentation will be posted in the Scientific Presentations section of the Tonix website following the session.

Tonix Pharmaceuticals Holding Corp.* 
Tonix is a fully-integrated biotech company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years. TNX-4200 is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. 

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners. 

This press release and further information about Tonix can be found at www.tonixpharma.com. 

Forward Looking Statements 
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. 

Investor Contact 
Jessica Morris 
Tonix Pharmaceuticals 
investor.relations@tonixpharma.com
(862) 799-8599 

Brian Korb 
astr partners 
(917) 653-5122 
brian.korb@astrpartners.com 

Media Contact 
Ray Jordan 
Putnam Insights 
ray@putnaminsights.com

Indication and Usage

Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.

Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.

Important Safety Information

Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:

  • discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw or stomach
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded

Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.

Do not use Zembrace or Tosymra if you have:

  • history of heart problems
  • narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
  • uncontrolled high blood pressure
  • hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.
  • had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation
  • severe liver problems
  • taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.
  • are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.
  • an allergy to sumatriptan or any of the components of Zembrace or Tosymra

Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.

Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.

Zembrace and Tosymra may cause serious side effects including:

  • changes in color or sensation in your fingers and toes
  • sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever
  • cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet
  • increased blood pressure including a sudden severe increase even if you have no history of high blood pressure
  • medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.
  • serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
  • hives (itchy bumps); swelling of your tongue, mouth, or throat
  • seizures even in people who have never had seizures before

The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).

Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.

This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.

You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Primary Logo

Source: Tonix Pharmaceuticals Holding Corp.

Released July 7, 2025

Nvidia Shatters Records: AI Giant Becomes World’s Most Valuable Company

Posted on by slightbourne@noblecapitalmarkets.com

In a stunning display of market dominance, Nvidia has officially entered uncharted territory by achieving a market capitalization of $3.92 trillion, surpassing Apple’s previous record and establishing itself as the most valuable company in corporate history.

The semiconductor giant’s shares surged as much as 2.4% to $160.98 during Thursday morning trading, propelling the company beyond Apple’s historic closing value of $3.915 trillion set on December 26, 2024. This milestone represents far more than a simple changing of the guard—it signals a fundamental shift in how markets value artificial intelligence infrastructure.

Nvidia’s ascent to unprecedented valuation levels reflects Wall Street’s unwavering confidence in the artificial intelligence revolution. The company’s specialized chips have become the essential building blocks for training the world’s most sophisticated AI models, creating what industry experts describe as “insatiable demand” for Nvidia’s high-end processors.

The magnitude of Nvidia’s valuation becomes even more striking when placed in global context. The company is now worth more than the combined value of all publicly listed companies in Canada and Mexico. It also exceeds the total market capitalization of the entire United Kingdom stock market, underscoring the extraordinary concentration of value in AI-related assets.

The transformation of Nvidia from a specialized gaming hardware company to Wall Street’s AI bellwether represents one of the most remarkable corporate evolution stories in modern business history. Co-founded in 1993 by CEO Jensen Huang, the Santa Clara-based company has seen its market value increase nearly eight-fold over the past four years, rising from $500 billion in 2021 to approaching $4 trillion today.

This meteoric rise has been fueled by an unprecedented corporate arms race, with technology giants Microsoft, Amazon, Meta Platforms, Alphabet, and Tesla competing to build expansive AI data centers. Each of these companies relies heavily on Nvidia’s cutting-edge processors to power their artificial intelligence ambitions, creating a virtuous cycle of demand for the chipmaker’s products.

Despite its record-breaking market capitalization, Nvidia’s valuation metrics suggest the rally may have room to run. The stock currently trades at approximately 32 times analysts’ expected earnings for the next 12 months—well below its five-year average of 41 times forward earnings. This relatively modest price-to-earnings ratio reflects the company’s rapidly expanding profit margins and consistently upward-revised earnings estimates.

The company’s remarkable recovery trajectory becomes evident when examining its recent performance. Nvidia’s stock has rebounded more than 68% from its April 4 closing low, when global markets were rattled by President Trump’s tariff announcements. The subsequent recovery has been driven by expectations that the White House will negotiate trade agreements to mitigate the impact of proposed tariffs on technology companies.

Nvidia’s dominance hasn’t gone unchallenged. Earlier this year, Chinese startup DeepSeek triggered a global equity selloff by demonstrating that high-performance AI models could be developed using less expensive hardware. This development sparked concerns that companies might reduce their spending on premium processors, temporarily dampening enthusiasm for Nvidia’s growth prospects.

However, the company’s ability to maintain its technological edge has kept it at the forefront of AI hardware innovation. Nvidia’s newest chip designs continue to demonstrate superior performance in training large-scale artificial intelligence models, reinforcing its position as the preferred supplier for major technology companies.

Nvidia now carries a weight of nearly 7.4% in the benchmark S&P 500, making it a significant driver of broader market performance. The company’s inclusion in the Dow Jones Industrial Average last November, replacing Intel, symbolized the semiconductor industry’s strategic pivot toward AI-focused development.

As Nvidia approaches the $4 trillion threshold, its unprecedented valuation serves as a barometer for investor confidence in artificial intelligence’s transformative potential across industries.